文献速递垂体与肾上腺疾病

药物治疗原发性醛固酮增多症的心血管代谢结局与死亡率:一项回顾性队列研究

Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study.
PubMed 文献 · Lancet Diabetes Endocrinol · 2017-11-09

本研究利用布里格姆妇女医院、麻省总医院及其附属合作医院的研究登记数据库,纳入1991—2016年评估的602例接受盐皮质激素受体拮抗剂治疗的原发性醛固酮增多症患者与41853例年龄匹配的原发性高血压患者。结果显示,原发性醛固酮增多症患者的心血管事件、死亡、糖尿病及心房颤动风险均高于原发性高血压患者,且超额风险主要见于肾素持续受抑制(<1 μg/L per h)者。

要点

  • 接受盐皮质激素受体拮抗剂治疗的原发性醛固酮增多症患者心血管事件发生率高于原发性高血压患者(校正HR 1.91)。
  • 死亡、糖尿病、心房颤动的校正风险亦升高,HR分别为1.34、1.26、1.93。
  • 超额风险仅限于肾素持续受抑制(<1 μg/L per h)者,肾素未受抑制者无显著超额风险。

核心结论

  • 当前原发性醛固酮增多症的盐皮质激素受体拮抗剂治疗实践,与原发性高血压患者相比,与更高的新发心血管代谢事件和死亡风险相关,且独立于血压控制。
  • 将盐皮质激素受体拮抗剂滴定至升高肾素可能减轻这一超额风险。

研究设计与样本

  • 回顾性队列研究,使用布里格姆妇女医院、麻省总医院及其附属合作医院的研究登记数据库。
  • 通过ICD-9和ICD-10编码识别1991—2016年评估、年龄至少18岁的原发性醛固酮增多症患者。
  • 排除接受肾上腺切除术、既往有心血管事件、未接受盐皮质激素受体拮抗剂治疗或研究入组后无随访就诊的患者。
  • 从同一登记库识别原发性高血压人群,按入组时年龄的十年段进行频数匹配。
  • 主要结局为新发心血管事件,定义为新发心肌梗死或冠状动脉血运重建、因充血性心力衰竭住院或卒中的复合终点,采用校正Cox回归模型评估。

主要发现

  • 共识别602例接受盐皮质激素受体拮抗剂治疗的原发性醛固酮增多症患者和41853例年龄匹配的原发性高血压患者。
  • 两组患者在整个研究期间的心血管风险特征和血压相当。
  • 原发性醛固酮增多症患者的心血管事件发生率高于原发性高血压患者(每1000人年56.3 [95% CI 48.8-64.7] vs 26.6 [26.1-27.2],校正HR 1.91 [95% CI 1.63-2.25];校正10年累积发生率差异为每100人超额14.1 [95% CI 10.1-18.0]起事件)。
  • 原发性醛固酮增多症患者的新发死亡(HR 1.34 [95% CI 1.06-1.71])、糖尿病(HR 1.26 [95% CI 1.01-1.57])和心房颤动(HR 1.93 [95% CI 1.54-2.42])校正风险亦更高。
  • 与原发性高血压相比,心血管事件和死亡的超额风险仅限于接受盐皮质激素受体拮抗剂治疗期间肾素活性仍受抑制(<1 μg/L per h)的原发性醛固酮增多症患者(校正HR分别为2.83 [95% CI 2.11-3.80]和1.79 [95% CI 1.14-2.80]),而接受较高剂量盐皮质激素受体拮抗剂且肾素未受抑制(≥1 μg/L per h)的患者无显著超额风险。

关键数值与推荐

  • 主要结局为新发心血管事件,定义为新发心肌梗死或冠状动脉血运重建、因充血性心力衰竭住院或卒中的复合终点。
  • 心血管事件发生率:原发性醛固酮增多症患者每1000人年56.3(95% CI 48.8-64.7)vs 原发性高血压患者每1000人年26.6(95% CI 26.1-27.2),校正HR 1.91(95% CI 1.63-2.25)。
  • 校正10年累积发生率差异为每100人超额14.1(95% CI 10.1-18.0)起事件。
  • 肾素活性仍受抑制(<1 μg/L per h)者心血管事件校正HR 2.83(95% CI 2.11-3.80),死亡校正HR 1.79(95% CI 1.14-2.80)。
  • 肾素未受抑制(≥1 μg/L per h)且接受较高剂量盐皮质激素受体拮抗剂者无显著超额风险。

临床怎么用

  • 作者认为,将盐皮质激素受体拮抗剂滴定至升高肾素可能减轻原发性醛固酮增多症患者的超额风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mineralocorticoid receptor (MR) antagonists are the recommended medical therapy for primary aldosteronism. Whether this recommendation effectively reduces cardiometabolic risk is not well understood. We aimed to investigate the risk of incident cardiovascular events in patients with primary aldosteronism treated with MR antagonists compared with patients with essential hypertension. METHODS: We did a cohort study using patients from a research registry from Brigham and Women's Hospital, Massachusetts General Hospital, and their affiliated partner hospitals. We identified patients with primary aldosteronism using International Classification of Disease, 9th and 10th Revision codes, who were assessed between the years 1991-2016 and were at least 18 years of age. We excluded patients who underwent surgical adrenalectomy, had a previous cardiovascular event, were not treated with MR antagonists, or had no follow-up visits after study entry. From the same registry, we identified a population with essential hypertension that was frequency matched by decade of age at study entry. We extracted patient cohort data and collated it into a de-identified database. The primary outcome was an incident cardiovascular event, defined as a composite of incident myocardial infarction or coronary revascularisation, hospital admission with congestive heart failure, or stroke, which was assessed using adjusted Cox regression models. Secondary outcomes were the individual components of the composite cardiovascular outcome, as well as incident atrial fibrillation, incident diabetes, and death. FINDINGS: We identified 602 eligible patients with primary aldosteronism treated with MR antagonists and 41 853 age-matched patients with essential hypertension from the registry. The two groups of patients had comparable cardiovascular risk profiles and blood pressure throughout the study. The incidence of cardiovascular events was higher in patients with primary aldosteronism on MR antagonists than in patients with essential hypertension (56·3 [95% CI 48·8-64·7] vs 26·6 [26·1-27·2] events per 1000 person-years, adjusted hazard ratio 1·91 [95% CI 1·63-2·25]; adjusted 10-year cumulative incidence difference 14·1 [95% CI 10·1-18·0] excess events per 100 people). Patients with primary aldosteronism also had higher adjusted risks for incident mortality (hazard ratio [HR] 1·34 [95% CI 1·06-1·71]), diabetes (1·26 [1·01-1·57]), and atrial fibrillation (1·93 [1·54-2·42]). Compared with essential hypertension, the excess risk for cardiovascular events and mortality was limited to patients with primary aldosteronism whose renin activity remained suppressed (<1 μg/L per h) on MR antagonists (adjusted HR [2·83 [95% CI 2·11-3·80], and 1·79 [1·14-2·80], respectively) whereas patients who were treated with higher MR antagonist doses and had unsuppressed renin (≥1 μg/L per h) had no significant excess risk. INTERPRETATION: The current practice of MR antagonist therapy in primary aldosteronism is associated with significantly higher risk for incident cardiometabolic events and death, independent of blood pressure control, than for patients with essential hypertension. Titration of MR antagonist therapy to raise renin might mitigate this excess risk. FUNDING: US National Institutes of Health.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Hundemer GL, Curhan GC, Yozamp N, et al. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2017. PMID: 29129576. doi:10.1016/S2213-8587(17)30367-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。